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A B S T R A C T
Background
Community-acquired pneumonia (CAP) is a lung infection that can be acquired during day-to-day activities in the community (not
while receiving care in a hospital). Community-acquired pneumonia poses a significant public health burden in terms of mortality,
morbidity, and costs. Shorter antibiotic courses for CAP may limit treatment costs and adverse effects, but the optimal duration of
antibiotic treatment is uncertain.
Objectives
To evaluate the efficacy and safety of short-course versus longer-course treatment with the same antibiotic at the same daily dosage for
CAP in non-hospitalised adolescents and adults (outpatients). We planned to investigate non-inferiority of short-course versus longer-
term course treatment for efficacy outcomes, and superiority of short-course treatment for safety outcomes.
Search methods
We searched CENTRAL, which contains the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE, Embase,
five other databases, and three trials registers on 28 September 2017 together with conference proceedings, reference checking, and
contact with experts and pharmaceutical companies.
1Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selection criteria
Randomised controlled trials (RCTs) comparing short- and long-courses of the same antibiotic for CAP in adolescent and adult
outpatients.
Data collection and analysis
We planned to use standard Cochrane methods.
Main results
Our searches identified 5260 records. We did not identify any RCTs that compared short- and longer-courses of the same antibiotic
for the treatment of adolescents and adult outpatients with CAP.
We excluded two RCTs that compared short courses (five compared to seven days) of the same antibiotic at the same daily dose because
they evaluated antibiotics (gemifloxacin and telithromycin) not commonly used in practice for the treatment of CAP. In particular,
gemifloxacin is no longer approved for the treatment of mild-to-moderate CAP due to its questionable risk-benefit balance, and reported
adverse effects. Moreover, the safety profile of telithromycin is also cause for concern.
We found one ongoing study that we will assess for inclusion in future updates of the review.
Authors’ conclusions
We found no eligible RCTs that studied a short-course of antibiotic compared to a longer-course (with the same antibiotic at the same
daily dosage) for CAP in adolescent and adult outpatients. The effects of antibiotic therapy duration for CAP in adolescent and adult
outpatients remains unclear.
P L A I N L A N G U A G E S U M M A R Y
Short- versus longer-course antibiotics for community-acquired pneumonia in non-hospitalised adolescents and adults
Review question
We investigated short- and longer-courses of antibiotics for adolescents and adults with community-acquired pneumonia (CAP) who
did not require admission to hospital.
Background
Community-acquired pneumonia is a common lung infection that can be acquired during day-to-day activities in the community (not
while receiving care in a hospital). Community-acquired pneumonia can be serious, and among older people and those with other
health problems it can cause death. Community-acquired pneumonia is treated with antibiotics. Short-course antibiotic treatment may
be effective, cheaper, and safer than longer treatment, but this needs to be demonstrated.
Search date
The evidence is current to 28 September 2017.
Key results
Our searches identified 5260 records, but no completed studies compared short- and longer-courses of the same antibiotic for treatment
of adolescents and adults in the community with CAP. The effect of length of antibiotic therapy on adolescents and adults with CAP
who are treated in the community remains unclear.
We excluded two studies that compared short courses (five versus seven days) of the same antibiotic at the same daily dose because they
evaluated antibiotics (gemifloxacin and telithromycin) that are not commonly used for people with CAP. Gemifloxacin is no longer
used because its risks do not appear be balanced with treatment benefit, and adverse treatment effects have been reported. The safety
of telithromycin has also raised concerns.
We found one ongoing study that we will assess for inclusion in future updates of the review.
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B A C K G R O U N D
Description of the condition
Pneumonia is an acute lung infection. Community-acquired
pneumonia (CAP) usually refers to pneumonia acquired outside
the hospital setting or that develops within 48 hours of hospital
admission. This contrasts with healthcare-associated pneumonia,
which is defined as pneumonia that develops after 48 hours of
hospital admission, or pneumonia that develops in hospital after
intubation (Kalil 2016;NICE 2014). Common clinical features of
CAP include cough, fever, painful breathing, fatigue, shortness of
breath, and night sweats (Broulette 2013). The diagnostic criteria
for pneumonia vary widely; some guidelines require the presence
of dense areas of the lung on a chest x-ray or other imaging tech-
nique (Torres 2013a), while others require the presence of respi-
ratory signs (abnormal breath sounds, such as localised crackles)
or symptoms only (Lim 2015).
Community-acquired pneumonia can be caused by different mi-
cro-organisms. The most common infective organism among out-
patients with non-severe pneumonia is Streptococcus pneumoniae
(Cillóniz 2012; Torres 2013a; Welte 2012).
Several factors are associated with increased risk of CAP, includ-
ing smoking, alcoholism, underlying medical conditions, nursing
home residency, or regular contact with children (Sahuquillo-Arce
2016; Torres 2013b).
Community-acquired pneumonia poses a high burden of mor-
tality, morbidity, and healthcare-associated costs worldwide (
Broulette 2013). Community-acquired pneumonia incidence
varies by country, age, and gender; the highest rates occur in older
people (34 per 1000 adults aged 75 years and over). The overall
annual incidence among adults in Europe ranges from 1.54 to
1.7 per 1000 population (Torres 2013b; Welte 2012; Woodhead
1987).
Lower respiratory tract infections, including pneumonia, are the
fourth most common cause of death globally (Lim 2012; Torres
2013b). The cost associated with hospital treatment of CAP is 5
to 10 times greater than outpatient treatment (Tichopad 2013;
Welte 2012).
Several studies have estimated an increase in antibiotic resistance in
CAP-related pathogens worldwide (Spellberg 2008; Welte 2012;
WHO 2014), which has important clinical and economic impli-
cations. The failure of antibiotic treatment due to resistance or an
inappropriate treatment choice may increase treatment cost if a
more expensive antibiotic class or longer hospital stay is required.
Description of the intervention
Adults diagnosed with CAP require effective antibiotic ther-
apy. Frequently used antibiotics are beta-lactams, cephalosporins,
macrolides, and fluoroquinolones (Torres 2013a). The choice of
antibiotic is commonly empirical, and individual study results
have not shown significant differences in efficacy among antibi-
otics or antibiotic groups (Pakhale 2014). Some factors impli-
cated with empirical treatment choices include potential aetiolog-
ical pathogens and their regional resistance profiles, the efficacy
and safety of individual antibiotics, and the treatment schedule
and its effect on adherence to treatment (Mandell 2007).
The duration of antibiotic therapy may be relevant in the man-
agement of people with CAP. Currently, there is a myriad of rec-
ommendations regarding the duration of treatment, but in most
cases, treatment courses are 5 to 14 days (Li 2007; Lim 2015;
Mandell 2007; Torres 2013a). People managed in the commu-
nity usually have less severe pneumonia, fewer comorbidities, and
may be younger, and so may not need prolonged courses of an-
tibiotic treatment (Holter 2016; NICE 2014). Administration
of short-course antibiotics has been proposed to avoid unneces-
sary pharmacy costs (less antibiotic consumed) and complications
(Bernal-Vargas 2016; Dinh 2016). Moreover, short-course antibi-
otic therapy has been associated with better patient compliance
and symptom resolution, without increased mortality or readmis-
sion rates (Uranga 2016).
How the intervention might work
The duration of antibiotic therapy is important in the manage-
ment of people with CAP. If the course of therapy is too short, it
may lead to treatment failure. Conversely, prolonged courses of an-
tibiotics contribute significantly to antibiotic overuse, which is as-
sociated with substantial costs, and may lead to increasing rates of
antibiotic resistance, Costelloe 2010; File 2004b; Karchmer 2004;
Segreti 2005, and potentially severe side effects, such as Clostrid-
ium difficile infection (Li 2007). Prolonged treatment also makes
treatment compliance more challenging (Kardas 2002).
Why it is important to do this review
Increased guideline adherence among prescribers can lead to sig-
nificant reductions in morbidity and mortality (Julián-Jiménez
2012; Welte 2012). Recommendations for antibiotic treatment
are based on illness severity, frequency of specific pathogens, local
microbial resistance patterns, and drug safety profiles. However,
the optimal length of antibiotic treatment for CAP remains un-
clear (Dinh 2016).
Several studies have aimed to determine the effects of antibi-
otic treatment duration on people with CAP. It has been sug-
gested that shorter regimens are as effective as longer courses,
and are safer, limiting the spread of drug-resistant bacteria, re-
ducing adverse effects (including C difficile infection), limiting
treatment costs, and improving compliance (Bernal-Vargas 2016;
Chalmers 2016; Dimopoulos 2008; Dinh 2016; Dunbar 2003; El
Moussaoui 2006; File 2004c; Garau 2008;Hopkins 1995; Kolditz
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2005; Li 2007; Mandell 2003; Pugh 2015; Socan 1998). Current
guidelines suggest courses of treatment that range from 5 days to
14 days (Eccles 2014; File 2003; File 2004c; Li 2007; Lim 2009;
Lim 2015; Mandell 2000; Mandell 2007; Restrepo 2005; Uranga
2016). However, most guidelines that suggest short courses were
developed for hospital inpatients, and there is a lack of evidence
with respect to treating CAP in community or outpatient settings.
This could explain the marked variability seen in clinical practice
regarding the length of antibiotic treatment for outpatients with
CAP (Lim 2009; Woodhead 2000).
There are several systematic reviews on the effects of the length
of treatment for people with CAP (Dimopoulos 2008; Li 2007),
including some Cochrane Reviews (Haider 2011; Lassi 2017).
However, these reviews compare different antibiotic regimens; no
Cochrane Review has explicitly addressed the effects of antibiotic
therapy duration with the same antibiotic for treating CAP in ado-
lescent or adult outpatients. We conducted this systematic review
to compare short- versus long-course of the same antibiotic.
O B J E C T I V E S
To evaluate the efficacy and safety of short-course versus longer-
course treatment with the same antibiotic at the same daily dosage
for CAP in non-hospitalised adolescents and adults (outpatients).
We planned to investigate non-inferiority of short-course versus
longer-term course treatment for efficacy outcomes, and superior-
ity of short-course treatment for safety outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), regardless of study hypoth-
esis (superiority, non-inferiority, or equivalence), were eligible for
inclusion. A superiority trial aims to determine whether one inter-
vention is superior to another (Piaggio 2012). A non-inferiority
trial aims to determine whether one (typically new) intervention
is no worse than a reference treatment (Piaggio 2012). An equiv-
alence trial aims to determine whether one (typically new) inter-
vention is therapeutically similar to another, usually an existing
treatment (Piaggio 2012). We included studies reported as full
text, those published as abstract only, and unpublished data. (See
Differences between protocol and review.)
Types of participants
Adolescent and adult non-hospitalised patients (also defined as
outpatients for this review) with community-acquired pneumonia
(CAP) of any severity initially treated in the community were
eligible for inclusion. We considered a study to be eligible for
inclusion when most participants were aged over 10 years. We
defined participants aged from 10 years to 19 years as adolescents,
and those aged over 19 years as adults (WHO 2010). However, we
planned to accept other definitions provided by the trial authors.
We planned to accept any definition of pneumonia so long as it
was based on explicit criteria. Some trial authors did not consider
chest x-ray as a valid diagnostic tool for pneumonia due to its low
sensitivity and consistency; moreover, interpretation of x-ray im-
ages to conclude that a person has pneumonia can be quite subjec-
tive (Albaum 1996; Hemilä 2009; Hopstaken 2004; Lim 2009).
Other diagnostic techniques, such as high-resolution computed
tomography (CT) scan, sputum cultures, or blood counts, may be
more sensitive, but they are rarely available in low-income coun-
tries (Syrjala 1998), and are not considered as first-line diagnos-
tic tools by guidelines in high-income countries (Braman 2006;
Lim 2009). We planned to assess the potential effects of diagnos-
tic techniques used in the heterogeneity of the review results in a
subgroup analysis. We considered pneumonia as ‘community-ac-
quired’ when acquired in the community, as opposed to acquired
in a healthcare facility, or if the participant had not recently been
in a healthcare facility or in contact with someone who had re-
cently been in a healthcare facility (MeSH Browser 2018).
We planned to include participants with additional infections if
the trial reported data specifically for CAP or if most (more than
50%) of the study population had CAP.
We planned to include participants attending or living in health-
care facilities where the risk of exposure to multidrug-resistant or-
ganisms was high (such as haemodialysis outpatients or people liv-
ing in nursing homes or residential facilities) if participants living
in the community constituted most (more than 50%) of the study
population. We planned to assess the potential effects of includ-
ing participants attending or living in healthcare facilities where
the risk of exposure to multidrug-resistant organisms was high in
a subgroup analysis. On the other hand, participants with CAP
who initially attended hospital emergency departments, but did
not require further hospital admission, were not considered to be
eligible.
Studies that included participants who were immunocompro-
mised or immunocompetent HIV-positive were eligible for inclu-
sion.
Types of interventions
We planned to include RCTs that assessed the effects of the dura-
tion of antibiotic monotherapy for CAP, that is comparing short-
versus long-courses of the same antibiotic administered by the
same route and the same daily dose. There was no restriction on
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the type of antibiotic used, the daily dose, or the frequency of
administration. We planned to include the following co-interven-
tions provided theywere not part of the randomised treatment: an-
titussives, antipyretics, bronchodilators, mucolytics, or any other
non-antibiotic agent.
Taking into account the variety of antibiotics used for CAP, it
was difficult to establish a cut-off point for defining an antibiotic
course as ’short’ or ’long’. Considering similar systematic reviews
and guidelines on the topic (Dimopoulos 2008; Li 2007; Lim
2009; Mandell 2007), we defined an antibiotic course as ’short’ if
it lasted seven days or less, and ’long’ if it lasted more than seven
days. When comparing two short courses or two long courses (e.g.
three days versus five days), we considered the shortest one to be
the ’short’ course. We decided we would not stratify the analysis
by antibiotic type. (See Differences between protocol and review.)
Types of outcome measures
Primary outcomes
Efficacy outcomes
1. Clinical response (reported as dichotomous data when
possible).
i) Defined as ‘resolution or improvement’ of baseline
symptoms and clinical signs related to pneumonia without the
need for additional or alternative antibiotic therapy. However, we
accepted any definition of clinical response as long as it was
based on explicit criteria reported by the trial authors. If data for
the combined outcome ‘resolution or improvement’ were not
reported, we considered data for resolution or improvement
alone.
ii) We assessed ‘clinical response’ at two time points: at
the end-of-therapy evaluation visit, and at the latest follow-up
evaluation visit. For the latter time point, the follow-up from the
beginning of treatment should have been at least 14 days. (See
Differences between protocol and review.)
2. Overall mortality rate (reported as dichotomous data
when possible). Defined as death due to any cause occurring
until the end of the follow-up period. The follow-up period from
the beginning of treatment should have lasted at least 14 days.
Safety outcomes
1. All adverse effects (dichotomous data, no minimum
follow-up defined).
2. Serious adverse effects (as reported by the study authors,
dichotomous data, no minimum follow-up defined). We did not
define death as a serious adverse event, as we considered
mortality as an efficacy outcome (see above). We followed the
terminology suggested by the Cochrane Handbook for Systematic
Reviews of Interventions for harms (Loke 2011):
i) adverse event: an unfavourable outcome that occurs
during or after the use of a drug or other intervention but is not
necessarily caused by it;
ii) adverse effect: an adverse event for which the causal
relation between the intervention and the event is at least a
reasonable possibility;
iii) adverse drug reaction: an adverse effect specific to a
drug;
iv) side effect: any unintended effect, adverse or beneficial,
of a drug that occurs at doses normally used for treatment;
v) complications: adverse events or effects following
surgical and other invasive interventions.
We anticipated that various types of adverse effects and adverse
events would be reported. We thus planned to narrow the focus,
as suggested by the Cochrane Handbook for Systematic Reviews of
Interventions (Loke 2011). We attempted to prepare a table de-
scribing all the safety outcomes of the included studies, and based
on our judgement about the relevance of the outcome for partici-
pants, we would subsequently have grouped the outcomes.
We did not consider withdrawals or dropouts as surrogate markers
for safety or tolerability because of the potential for bias (Loke
2011). However, if this had been the only safety information re-
ported, we would have extracted these data.
Secondary outcomes
1. Mortality attributable to pneumonia (reported as
dichotomous data when possible). Defined as death due to
pneumonia occurring until the end of the follow-up period. The
follow-up period from the beginning of treatment should have
been at least 14 days.
2. Hospitalisation due to pneumonia (reported as
dichotomous data when possible). Defined as the need for
hospital admission until the end of the follow-up period. We
preferably considered hospital admissions due to pneumonia.
However, if this outcome was not reported, we considered
hospital admission for any cause.
3. Relapse rate defined as the reappearance of signs and
symptoms of pneumonia in participants deemed clinically cured
or improved (follow-up period not defined).
4. Radiological response (reported as dichotomous data
when possible). Defined as reaching resolution or improvement
of radiographic findings after antibiotic therapy. The follow-up
period from the beginning of treatment should have been at least
14 days.
5. Patient satisfaction with treatment (measured using a
validated tool).
Reporting one of more of the outcomes listed here in the trial was
not an inclusion criterion of the review.
Search methods for identification of studies
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See Differences between protocol and review for this section.
Electronic searches
We searched the following databases up to 28 September 2017:
1. Cochrane Acute Respiratory Infections Group Specialised
Register (searched 28 September 2017);
2. Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 9) in the Cochrane Library (searched
28 September 2017) (Appendix 1);
3. Database of Abstracts of Reviews of Effects (DARE; the
Cochrane Library, Issue 9, 2017) and NHS Economic
Evaluation Database (NHS EED; the Cochrane Library, Issue 9,
2017) (Appendix 1). These databases ceased publication in
March 2015 and have now been searched completely.
4. MEDLINE (Ovid) (1946 to 28 September 2017)
(Appendix 1);
5. Embase (Elsevier) (1974 to 28 September 2017) (Appendix
2);
6. Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCO) (1981 to 28 September 2017) (Appendix
3);
7. Latin American and Caribbean Health Sciences Literature
Database (LILACS) via Virtual Health Library (VHL) (1982 to
28 September 2017) (Appendix 4);
8. OpenGrey (www.opengrey.eu) (accessed 28 September
2017) (Appendix 5);
9. ProQuest Dissertations & Theses Database (1734 to 28
September 2017) (Appendix 6); and
10. Web of Science Conference Proceedings Citation Index
Science (WoS CPCI-S) (1990 to 28 September 2017) (Appendix
7).
The MEDLINE search was used to search CENTRAL, DARE,
andNHSEED, andwas combinedwith theCochraneHighly Sen-
sitive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximising version (2008 revi-
sion); Ovid format to search MEDLINE (Lefebvre 2011).
We searched the following trials registries on 25 September 2017
(Appendix 8):
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( clinicaltrials.gov);
2. ISRCTN registry ( www.isrctn.com); and
3. WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch).
We did not restrict results by language or publication status.
Searching other resources
We checked reference lists of potentially eligible studies (File 2007;
Tellier 2004), review articles (Afshar 2009; Biondi 2014; Cordero
2013; Dawson-Hahn 2017; Marras 2004; Migliori 2012; Sazawal
2003; Simpson 2005; Troitino 2013; Vardakas 2008; Yu 2008),
and clinical guidelines for additional references (Aliberti 2010;
Mandell 2007;Woodhead 2011).We also used theWeb of Science
(WoS) citation map to track articles that had cited File 2007 and
Tellier 2004. We did not handsearch journals, because all journals
that appeared to have a high yield of relevant studies had been
handsearched on behalf of Cochrane.
We contacted experts to identify additional unpublishedmaterials.
We contacted the following pharmaceutical companies to identify
further published or unpublished studies eligible for inclusion:
Abbott, AstraZeneca, Aventis, Boehringer-Ingelheim, Bristol-My-
ers Squibb, Chiesi, Faes Farma, GlaxoSmithKline Beecham,Hoff-
mann-LaRoche, Lilly, Merck, Merck Sharp & Dohme, Novartis,
Pfizer, Pharmacia, Sanofi, and Yamanouchi.
We checked abstracts presented at the following conferences
(from 2004 onward): European Respiratory Society (ERS) (2004
to 2017); American Association for Respiratory Care (AARC)
(2004 to 2016); British Thoracic Society (BTS) winter and sum-
mer meetings (2004 to 2016); Primary Care Respiratory Soci-
ety (PCRS) - UK National Primary Care Conference (2004 to
2009; 2012 to 2017); Sociedad Española de Medicina de Familia
y Comunitaria (semFYC) (2004 to 2017); Sociedad Española de
Médicos de Atención Primaria (SEMERGEN) (2004 to 2017);
Sociedad Española de Medicina Interna (SEMI) (2004 to 2016);
Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
(2004 to 2017); and Sociedad Española de Neumología Pediátrica
(NEUMOPED) (2005; 2007 to 2012; 2014 to 2017).
Data collection and analysis
Selection of studies
Two review authors (RRB or JRS or JMG or JMMG or CRF or
JMC or JCC or MGG or JHM or AAL or VHS) independently
screened titles and abstracts for inclusion.We retrieved the full-text
study reports/publications of potentially relevant studies, and two
review authors (RRB or JRS or JMG or JMMGor CRF or JMC or
JCC or MGG or JHM or AAL or VHS) independently screened
the full-texts and identified studies for inclusion and identified
and recorded reasons for exclusion of ineligible studies. Any dis-
agreements were resolved through discussion or by consulting a
third review author (JLA) if necessary. We identified and excluded
duplicates and collated multiple reports of the same study so that
each study, rather than each report, was the unit of interest in the
review. We recorded the selection process in sufficient detail to
complete a PRISMA flow diagram and Characteristics of excluded
studies tables (Moher 2009).
Data extraction and management
We planned to use a data collection form for study characteristics
and outcome data that had been piloted on one study in the re-
view. Two review authors (JLA, RRB or JHM) planned to extract
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study characteristics from included studies in duplicate.We would
have extracted the following study characteristics using Covidence
software (Covidence 2017).
1. Verification of study eligibility.
2. Data sources.
3. Study details: sponsorship source, country, setting, author’s
contact details.
4. Methods:
i) unit and method of allocation;
ii) design: parallel/cross-over/factorial/other;
iii) study phase: I; II; III; IV;
iv) number of arms and allocation ratio;
v) study aim; and
vi) interim analyses and stopping rules.
5. Population:
i) inclusion criteria;
ii) exclusion criteria;
iii) total sample size and number of participants allocated
per group; and
iv) baseline characteristics.
6. Interventions:
i) intervention characteristics: antibiotics used, doses,
duration, and frequency;
ii) intervention fidelity;
iii) co-interventions; and
iv) feasibility.
7. Equity: exclusion of disadvantaged groups.
8. Outcomes:
i) time frame;
ii) study hypothesis: superiority/non-inferiority/
equivalence;
iii) margin of non-inferiority or equivalence;
iv) outcome measurement;
v) assumed risk and sample estimate; and
vi) results per outcome: results, measure of effect,
statistical significance, follow-up duration.
9. ’Risk of bias’ tool domains.
We planned that two review authors (JLA, RRB or JHM) would
independently extract outcome data from the included studies.
We planned to note in the Characteristics of included studies table
if outcome data had not been reported in a usable way. Any dis-
agreements would have been resolved by consensus or by involv-
ing a third review author (JLA or RRB). One review author (JLA)
would have transferred the data into Review Manager 5 (Review
Manager 2014). We planned to double-check that data were en-
tered correctly by comparing the data presented in the systematic
review with the study reports. A second review author (RRB or
JHM) would have spot-checked study characteristics for accuracy
against the trial report.
Assessment of risk of bias in included studies
We planned to independently assess risk of bias for each study
using the criteria outlined in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011a). Any disagreements
would have been resolved by discussion or by involving another
review author. We would have assessed the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We planned to assess the following domains for each study as a
whole (therefore by a single entry in the ’Risk of bias’ tool for
each study): random sequence generation; allocation concealment;
baseline imbalance; blinding of participants and personnel; and
selective outcome reporting. We planned to assess blinding of out-
come assessment and incomplete outcome data separately for each
outcome (and each time point if several time points were consid-
ered).We would have classified susceptibility to lack of blinding of
the outcome assessment as low for overall mortality and all-cause
hospitalisations, and high for the remaining outcomes.
In trials attempting to establish non-inferiority, per-protocol (PP)
analysis may be desirable as a protection from the tendency of
intention-to-treat (ITT) analyses to bias the results towards no
difference (falsely concluding non-inferiority) (Higgins 2011a;
Piaggio 2012). For outcomes testing non-inferiority, we therefore
planned to consider the domain ’incomplete outcome data’ to be
at low risk of bias if results from both analyses (PP and ITT) were
consistent.
However, many consider that available-case and ITT analyses are
not appropriate when assessing adverse effects, as it is wrong to
attribute these to a treatment that somebody did not receive (
Higgins 2011a). For this reason, for safety outcomes, we planned
to consider the domain ’incomplete outcome data’ to be at low
risk of bias if the results from both analyses (PP and ITT) were
consistent.
When considering treatment effects, we planned to take into ac-
count the risk of bias for the studies that contributed to that out-
come.
See Differences between protocol and review.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
reported deviations in Differences between protocol and review.
Measures of treatment effect
We planned to enter outcome data for the included studies into
data tables in Review Manager 5 to calculate treatment effects
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(Review Manager 2014). We planned to use odds ratio (OR) for
dichotomous outcomes, and to perform available-case analyses of
the PP populations (re-analysed by the review authors if needed).
We planned to perform meta-analyses only where this was mean-
ingful, that is if the treatments, participants, and the underlying
clinical question were similar enough for pooling to make sense.
Unit of analysis issues
Weplanned to obtain data considering the participant (rather than
the event) as the unit of analysis. If we found unit of analysis
errors, we planned to apply recommendations provided inChapter
9 of the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011).
Dealing with missing data
Weplanned to contact study investigators to verify key study char-
acteristics and to obtain missing numerical outcome data where
possible (e.g. when a study was available only as an abstract).
Where thiswas not possible, we planned todescribemissing partic-
ipant data by reporting proportions of randomised participants for
whom no outcome data were obtained (with reasons) by outcome
and randomised group in the ’Risk of bias’ tables. We planned to
address the potential impact of missing outcomes on the results of
the included studies in a sensitivity analysis. For all outcomes (ben-
efits and harms), we planned to repeat the analysis carrying out
analyses on the ITT principle; if there were missing data, and we
could not obtain additional information, we planned to perform
an available-case analysis. We also planned to perform sensitivity
analyses to assess how sensitive results were to changes in assump-
tions made in the available-case analysis (see Sensitivity analysis).
We planned to establish non-inferiority for potential benefit out-
comes. We defined the primary analysis to be PP, because this is
the most sensitive approach to detect any difference in efficacy
between groups (EMEA 2004). Per-protocol analysis considers re-
sults only from those participants who completed the trial and
who complied with or received some of the allocated intervention
(Higgins 2011b). On the other hand, ITT or available-case anal-
yses may not be the most appropriate analyses when attempting
to establish non-inferiority of a treatment (CRD 2009; Higgins
2011b), as they may tend to bias results towards no difference.
Intention-to-treat analysis fulfils the following principles: 1) keeps
participants in the intervention groups to which they were ran-
domised, regardless of the intervention they actually received; 2)
there is a measurement of outcome data on all participants; and
3) includes all randomised participants in the analysis (Higgins
2011a). Available-case analysis includes data only for those partic-
ipants whose results are known, using the total number of people
who had data recorded for the particular outcome in question as
a denominator (Higgins 2011a).
We planned to establish superiority and defined the primary anal-
ysis to be PP for potential harms. Intention-to-treat analysis may
not be appropriate when assessing harms, because it is wrong to at-
tribute these to a treatment that somebody didnot receive (Higgins
2011a).
If the trials reported ITT or PP results exclusively (and it was not
possible to re-analyse data), we planned to perform the analysis
using the results provided in the studies.
Assessment of heterogeneity
We planned to check for heterogeneity for each outcome by ex-
amining:
1. the characteristics of the studies;
2. the forest plot of results of the studies. We planned to
display study results graphically and check symmetry of the
results visually;
3. the results of the Chi² test for statistical heterogeneity (we
considered a significant P value to be P < 0.10); and
4. the results of the I² statistic for quantification of statistical
heterogeneity. The I² statistic describes the percentage total
variation across studies due to heterogeneity rather than chance.
We planned to judge the importance of the observed value of the
I² statistic depending on the magnitude and direction of effects
and the strength of evidence for heterogeneity (we defined
moderate-to-high heterogeneity as I² > 50%) (Deeks 2011).
Assessment of reporting biases
We planned to assess publication bias by means of a funnel plot
for each outcome. We planned to assess funnel plot asymmetry
statistically. If there was evidence of asymmetry, we planned to
consider publication bias as only one of a number of possible
explanations.
Data synthesis
We planned to combine outcome measures from individual trials
in a meta-analysis to provide a pooled effect estimate for each
outcome only if there were enough studies (at least two studies),
and if they were clinically and methodologically similar. If we
detected statistical heterogeneity (I² > 50% or by observation), or
if we deemed the meta-analysis inappropriate for other reasons,
we planned not to combine results but to undertake a narrative
analysis of studies, providing a descriptive presentation of results
with supporting tables. If we conducted a meta-analysis, and the
number of trials for each outcome measure was greater than three,
we planned to use a random-effects model; if there were two trials,
we would use the fixed-effect model (Deeks 2011). We planned
to assess the influence of the statistical model used to pool data on
the effects being evaluated in a sensitivity analysis (see Sensitivity
analysis). We planned to perform statistical analyses using Review
Manager 5, and to present results with 95% confidence interval
(CI) (Review Manager 2014).
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Hypotheses tested
We planned to investigate non-inferiority for efficacy outcomes,
and superiority for harms. For non-inferioritywe predefined amar-
gin (1) of 10% (i.e. relative differences of 10 percentage points).
We selected this margin as suggested by the European Medicines
Agency (EMEA 2004). However, we acknowledge that it is diffi-
cult to justify this choice, because our review could have included
different types of antibiotics (each with different efficacy against
placebo) and outcomes.
Non-inferiority for efficacy outcomes
We planned to classify short antibiotic courses as superior, non-
inferior, inconclusive, or inferior, according to definitions from
the extension of the CONSORT statement for non-inferiority
trials (Piaggio 2012). We considered the short antibiotic course
according to the following classification.
a. Desirable outcomes (1: OR = 0.9)
Desirable outcomes included clinical cure at the end-of-therapy
evaluation visit; clinical cure at the latest follow-up evaluation visit;
radiological response; and patient satisfaction with treatment. We
classified the findings as explained below (adapted from Piaggio
2012).
• The short course is superior (A): the whole 95% CI lies to
the right of OR = 1.
• The short course is non-inferior.
◦ Non-inferior but not shown to be superior (B andC):
the whole 95% CI lies to the right of 1 (OR = 0.9) and includes
OR = 1.
◦ Non-inferior and also shown to be inferior (D): the
whole 95% CI lies wholly to the right of 1 (OR = 0.9) and
wholly to the left of OR = 1. It is also inferior in the sense that a
null treatment difference is excluded. This circumstance is rare:
it requires a very large sample size and can also result from a non-
inferiority margin that is too wide.
• The result regarding non-inferiority of the short course is
inconclusive.
◦ The result regarding non-inferiority of the short
course is inconclusive, and the difference is non-significant (E
and F): the 95% CI includes 1 (OR = 0.9) and OR = 1.
◦ The result regarding non-inferiority of the short
course is inconclusive, but the difference is statistically significant
(G): the 95% CI includes 1 (OR = 0.9) and is wholly to the left
of OR = 1. This CI is inconclusive in that it is still plausible that
the true treatment difference is more than 1, but the new
treatment is significantly worse than the standard.
• The short course is inferior (H): the whole 95% CI is to the
left of 1 (OR = 0.9).
b. Undesirable outcomes (1: OR = 1.1)
Undesirable outcomes: overall mortality; mortality attributable to
pneumonia; hospitalisation due to pneumonia; all-cause hospital-
isations; and relapse rate. We classified the findings as explained
below (adapted from Piaggio 2012).
• The short course is superior (A): the whole 95% CI lies to
the left of OR = 1.
• The short course is non-inferior.
◦ Non-inferior but not shown to be superior (B andC):
the whole 95% CI lies to the left of 1 (OR = 1.1) and includes
OR = 1.
◦ Non-inferior and also shown to be inferior (D): the
whole 95% CI lies wholly to the left of 1 (OR = 1.1) and wholly
to the right of OR = 1. It is also inferior in the sense that a null
treatment difference is excluded. This circumstance is rare: it
requires a very large sample size and can also result from a non-
inferiority margin that is too wide.
• The result regarding non-inferiority of the short course is
inconclusive.
◦ The result regarding non-inferiority of the short
course is inconclusive, and the difference is non-significant (E
and F): the 95% CI includes 1 (OR = 1.1) and OR = 1.
◦ The result regarding non-inferiority of the short
course is inconclusive, but the difference is statistically significant
(G): the 95% CI includes 1 (OR = 1.1) and is wholly to the
right of OR = 1. This CI is inconclusive in that it is still plausible
that the true treatment difference is less than 1, but the new
treatment is significantly worse than the standard.
• The short course is inferior (H): the whole 95% CI is to the
right of 1 (OR = 1.1).
GRADE and ’Summary of findings’ tables
We planned to create a ’Summary of findings’ table using the fol-
lowing outcomes: clinical cure (at the end of therapy evaluation
visit); clinical cure (at the latest follow-up evaluation visit); over-
all mortality; all adverse effects; serious adverse effects; mortality
attributable to pneumonia; and hospitalisations due to pneumo-
nia. We planned to use the five GRADE considerations (study
limitations, consistency of effect, imprecision, indirectness, and
publication bias) to assess the quality of a body of evidence as it
related to the studies that contributed data to the analyses for the
prespecified outcomes (Atkins 2004). We planned to use meth-
ods and recommendations described in Section 8.5 and Chap-
ter 12 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011c), employing GRADEpro GDT software
(GRADEpro GDT 2014). We planned to justify all decisions to
down- or upgrade study quality using footnotes, and provide com-
ments to aid the reader’s understanding of the review where nec-
essary.
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Subgroup analysis and investigation of heterogeneity
We planned to undertake the following subgroup analyses.
1. Age of participants: more than 50% of participants were
aged 10 to 18 years versus more than 50% of participants were
adults (aged 19 to 74 years) versus more than 50% of
participants were aged 75 years or over.
2. Diagnosis of pneumonia: exclusively based on clinical signs
and symptoms versus also based on radiographic (or other image
techniques) findings.
3. Presence of relevant comorbidity: studies including
participants with relevant comorbidity (e.g. chronic pulmonary
disease, congestive heart failure, myocardial disease,
cerebrovascular disease, smokers) versus studies excluding these
participants.
4. Risk of exposure to multidrug-resistant organisms: studies
excluding participants living in healthcare facilities where the risk
of exposure to multidrug-resistant organisms is high (such as
nursing homes or residential facilities) versus studies including
these participants.
5. Severity of pneumonia: measured with a validated scale,
such as the pneumonia severity index (PSI) or CURB-65.
6. The degree of missing outcome data across studies:
outcomes with levels of missing data described during the ’Risk
of bias’ assessment stage as enough to induce clinically relevant
bias in the intervention effect estimate versus outcomes with
levels of missing data described as not enough to induce
clinically relevant bias in the intervention effect estimate.
7. Population sets: trials with PP analysis versus trials with
ITT analysis.
8. Study hypothesis: non-inferiority versus equivalence versus
superiority.
Sensitivity analysis
If there were sufficient included studies (at least two), we planned
to undertake sensitivity analyses to explore the influence of the
following factors on the robustness of results.
1. Allocation concealment: we planned to exclude studies with
inadequate or unclear allocation concealment from the meta-
analysis.
2. Statistical model chosen for meta-analysis: we planned to
use a fixed-effect model for meta-analyses performed with a
random-effects model, and to use a random-effects model for
meta-analyses based on a fixed-effect model in the first place.
3. Population sets: we planned to repeat the analysis carrying
out analyses based on the ITT principle.
4. Assumptions taken in the available-case analysis: we
planned to perform an analysis with imputation of missing data.
i) For dichotomous outcomes, we planned to consider
best-case and worst-case scenarios (Gamble 2005). We defined
the best-case scenario as all participants with missing outcomes
in the experimental intervention group having good outcomes,
and all those with missing outcomes in the control intervention
group having poor outcomes. The worst-case scenario would be
the converse (Higgins 2011b).
ii) For continuous data, we planned to conduct a
sensitivity analysis assuming a fixed difference between the actual
mean for the missing data and the mean assumed by the analysis
(Higgins 2011b).
R E S U L T S
Description of studies
Results of the search
We searched electronic databases to 28 September 2017 and iden-
tified 5260 records. Our searches of other sources identified six
additional records. Following removal of duplicates, we assessed
2844 records by title and abstract, and excluded 2800 records
that did not match our inclusion criteria. We retrieved 44 full-
text reports for further assessment and excluded 43 full-text ar-
ticles that did not meet the eligibility criteria (Excluded studies;
Characteristics of excluded studies; Figure 1). We did not identify
any trials for inclusion. However, we identified one ongoing trial
(NCT02903836).
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Figure 1. Study flow diagram.
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Included studies
We did not identify any trials for inclusion.
Excluded studies
We excluded 43 publications for the following reasons (
Characteristics of excluded studies; Figure 1).
1. Ineligible participants. The initial CAP treatment was
provided at a hospital for inpatients (CAP not initially treated in
the community) (n = 7; Aliberti 2017; Demartini 2004; El
Moussaoui 2006; Lagler 2012; Marti 2017; McCabe 1989; Van
den Brande 1997).
2. Ineligible intervention. The antibiotic is not in current use
for CAP (File 2007, reported in three publications; Tellier 2004,
reported in five publications).
3. Ineligible intervention. The study did not assess the effects
of antibiotic therapy duration (n = 3; Donowitz 1997;
Hammerschlag 2003; Rovira 1999).
4. Ineligible comparison. There were differences between
study arms in antibiotic dose (n = 7; Dunbar 2003; Dunbar
2004; File 2004a; Oldach 2015; Schonwald 1999; Zhao 2015;
Zhao 2016).
5. Ineligible study design (n = 18). Studies were based on
pooled data from other RCTs (Niederman 2004a; Van Rensburg
2005); presented a subgroup analysis (Shorr 2005); presented
post hoc analysis (Niederman 2004b); or were not randomised
designs (n = 14; Coley 2000; Darkes 2003; Fekete 2016; File
2005; Fogarty 2001; Hagberg 2003; Hammerschlag 2007;
Hammerschlag 2008; Hemenway 2014; Khashab 2006; Li 2007;
Lorenz 2003; Queen 2014; Rasche 2015).
Two RCTs compared short courses of the same antibiotic at the
same daily dose (File 2007; Tellier 2004). The studies compared
a five-day course versus a seven-day course of telithromycin (800
mg/day), Tellier 2004, or gemifloxacin (320 mg/day), File 2007,
for the treatment of CAP in adults. These studies did not com-
pare short- (seven days or less) and long- (more than seven days)
antibiotic courses (File 2007; Tellier 2004). Regarding effective-
ness, these studies could not rule out whether or not the shorter
course was superior to the longer course. Following the sugges-
tion of the Cochrane Acute Respiratory Infections editorial team,
we excluded these studies because they evaluated antibiotics not
commonly used in clinical practice for treatment of CAP. More-
over, according to the European Medicines Agency, gemifloxacin,
File 2007, is no longer approved for the treatment of mild-to-
moderate CAP due to its questionable risk-benefit relationship
(EMEA 2009). The safety profile of telithromycin, Tellier 2004,
is also cause for concern (Brinker 2006; Dore 2007; Ross 2007;
Wilde Mathews 2006). Further details are provided in Overall
completeness and applicability of evidence.
Ongoing trials
We identified one ongoing trial from ClinicalTrials.gov (
NCT02903836). The estimated study completion date was
September 2017.
Risk of bias in included studies
No studies fulfilled the review inclusion criteria. We could not
assess risk of bias.
Effects of interventions
No studies fulfilled the review inclusion criteria.
D I S C U S S I O N
Summary of main results
We did not identify any studies that compared short- and longer-
courses of the same antibiotic for the treatment of adolescents and
adult outpatients with CAP.
We excluded two RCTs that compared short courses (five com-
pared to seven days) of the same antibiotic at the same daily dose
because they evaluated antibiotics not commonly used in practice
for the treatment of CAP (File 2007; Tellier 2004). In particu-
lar, gemifloxacin, File 2007, is no longer approved for the treat-
ment of mild-to-moderate CAP due to its questionable risk-bene-
fit balance and reported adverse effects (EMEA 2009). Moreover,
the safety profile of telithromycin, Tellier 2004, is also cause for
concern (Brinker 2006; Dore 2007; Ross 2007; Wilde Mathews
2006). Furthers details are provided in Overall completeness and
applicability of evidence.
Overall completeness and applicability of
evidence
Because no studies fulfilled the review inclusion criteria, we could
not compare short- and longer-courses of antibiotics for the treat-
ment of CAP. Randomised controlled trial evidence comparing
different durations of antibiotic treatment for CAP is therefore
incomplete.
We were surprised by the absence of RCTs because CAP is a
relevant health problem; antibiotics are interventions commonly
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used in practice; and this research area is not new. This absence
may be explained by the following reasons. First, we defined as
eligible people with CAP of any severity, initially treated in the
community; we therefore excluded seven RCTs because initial
CAP treatment was provided to hospital inpatients (Aliberti 2017;
Demartini 2004; El Moussaoui 2006; Lagler 2012; Marti 2017;
McCabe 1989; Van den Brande 1997). Second, we attempted
to disentangle the effects of the duration of the treatment. As a
consequence, we excluded studies in which the antibiotic treat-
ment duration was not the only difference between study arms
(Donowitz 1997; Hammerschlag 2003). Third, we found difficul-
ties associated with evaluation of non-inferiority or equivalence,
which present a number of methodological challenges, in addi-
tion to the methodological problems that any superiority study
must overcome (Piaggio 2012). Fourth, we restricted our review to
RCTs and excluded studies that used data gathered retrospectively,
or studies that made use of subgroup analyses of RCTs. Finally,
we decided to exclude two RCTs that were otherwise eligible for
inclusion in the review because the antibiotics evaluated (gemi-
floxacin in File 2007 and telithromycin in Tellier 2004) are not
commonly used in practice for the treatment of CAP (File 2007;
Tellier 2004). Neither gemifloxacin nor telithromycin is recom-
mended by guidelines as a first-line option for the treatment of
CAP (Mandell 2007; NICE 2014), and their risk-benefit balance
is unclear.
Gemifloxacin is no longer approved for the treatment of mild-to-
moderate CAPdue to its questionable risk-benefit balance (EMEA
2009). Similarly, the safety profile of telithromycin is cause for
concern. Although we identified relevant information, we did not
include this evidence in the reviewbecause the corresponding stud-
ies did not fulfil our eligibility criteria. We found that an initial
analysis of 12 cases provided evidence for a rare, unusual form of
hepatotoxicity associated with telithromycin and characterised by
short latency, systemic symptoms and, in some cases, significant
ascites (Brinker 2006). Telithromycin was also the subject of two
investigations in the USA relating to potentially fraudulent safety
data and inappropriate trial methodology when submitted for US
Food and Drug Administration (FDA) approval. The FDA did
not include a warning until 16 months after the first cases of liver
injury were reported (Ross 2007). An analysis of the FDA’s post-
marketing database showed that the rate of reporting of acute liver
failure was 3.5 to 11 times higher for telithromycin compared to
other antibiotics marketed for similar indications. This implies
a reporting rate of 167 cases of acute liver failure per 1 million
person-years of telithromycin use, against the expected rate of 1
case per 1 million person-years (Wilde Mathews 2006). The FDA
Adverse Event Reporting System showed that the risk of hepato-
toxicity is 82% greater with telithromycin than with other agents
(Dore 2007).
Quality of the evidence
We found no evidence that compared short- and longer-courses
(more than seven days) of the same antibiotic for the treatment of
adolescent and adult outpatients with CAP. This review did not
identify any RCTs that studied this question.
Potential biases in the review process
We attempted to minimise bias by following Cochrane standard
methods. In particular, we would like to discuss the following
items.
Selection criteria
When writing the protocol for this review, we were not aware of
the existence of core outcomes sets for clinical trials, that is agreed
standardised sets of outcomes, such as those proposed by the Core
Outcome Measures in Effectiveness Trials (COMET) Initiative
(COMET 2010).We therefore did not select our review outcomes
according to those proposed by Barlow 2003.We did not consider
some of the outcomes as defined in this set, in particular symptoms
measured as Community-Acquired Pneumonia Symptom Ques-
tionnaire (CAP-Sym) (Lamping 2002), time to clinical stability
(Halm 2002), and 30-day post-admission mortality (Mortensen
2002). We did consider some of the proposed outcomes, such as
adverse effects, and we think that the review outcomes addressed
endpoints relevant to patients.
We excluded studies that analysed selected subgroups of the ran-
domised participants, for example those thatmade use of subgroup
analyses. We consider this to be a strength of our review, because
we attempted to maximise the external validity of our review re-
sults to unselected patients presenting to their physician (Pakhale
2014).
Two RCTs fulfilled our eligibility criteria (File 2007; Tellier 2004).
However, we decided to exclude these trials due to the worry-
ing safety profiles of the antibiotics evaluated, gemifloxacin and
telithromycin (Dore 2007; EMEA 2009; Brinker 2006; Ross
2007; Wilde Mathews 2006). We are aware of the possibility of
introducing bias by the post hoc exclusion of these two studies,
but we made this decision based on advice from the Cochrane
Acute Respiratory Infections editorial team.
Search methods for identification of studies
We performed our searches as comprehensively as possible accord-
ing to our resources.We aimed to reduce the risk of publicationbias
and to identify as much relevant evidence as possible. A healthcare
librarian designed the searches adapted to existing terminology.
We also contacted experts in the field and pharmaceutical compa-
nies, and handsearched conference abstracts. We did not limit the
searches by language of publication. However, it is possible that
we missed some trials not published in mainstream journals.
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We did not search for data reported in drug regulatory material
because we had neither the resources nor the expertise within our
team to do so. Moreover, we felt there was no methodological
guidance to accomplish this task. Searching for drug regulatory
material seems important because, due to the absence of included
studies, it is possible that the consideration of this information
may change review conclusions, especially for harms.
Equity, sex and gender issues
Wedid not assess equity or sex and gender issues in an explicit way.
Future updates of this review will follow the guidance proposed
by the Campbell and Cochrane Equity Methods Group, Equity
Checklist 2012, and the sex and gender in systematic reviews plan-
ning tool (Doull 2011).
Synthesising non-inferiority
There is no Cochrane guidance to synthesise evidence of non-infe-
riority or equivalence. This guidance is needed for several key steps
of the review process, such as the analysis strategy (ITT principle
or PP), or the meta-analysis itself (Witte 2004). We anticipate
that systematic reviews addressing non-inferiority or equivalence
will be more frequent due to non-inferiority trials having become
common place in recent years, so that this guidance is urgently
needed (Witte 2004).
Agreements and disagreements with other
studies or reviews
No studies fulfilled the inclusion criteria of this review.
We found two systematic reviews that compared the effects of an-
tibiotic treatment duration for CAP (Dimopoulos 2008; Li 2007)
. However, no study included in these reviews met all the eligibility
criteria for our review. Li 2007, which included RCTs compar-
ing courses of antibiotic of seven days or less with longer periods,
did not find differences in effectiveness or safety. An important
limitation of these findings is the under-representation of some
types of commonly used antibiotics, such as doxycycline. More-
over, most included participants had mild or moderate pneumo-
nia. Dimopoulos 2008 included seven clinical trials, two of which
were File 2007 and Tellier 2004, already discussed in our review;
the other trials were not eligible for our review because they in-
cluded children, hospitalised patients, or because the study arms
considered the same antibiotic in different dosages. Dimopoulos
2008 did not find differences regarding clinical effectiveness, mor-
tality, or adverse effects between short and long antibiotic cycles,
although the number of participants assessed was small.
A recent RCT evaluated the use of shorter antibiotic regimens ver-
sus standard care for treating CAP (Uranga 2016). The researchers
found that shorter courses could be as effective, if notmore so, than
conventional therapy with regard to patient recovery, without an
increase in adverse outcomes such as mortality and readmission.
However, this study was based on hospital inpatients, therefore
the findings may not extrapolate to outpatient settings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no eligible randomised controlled trials (RCTs) that
studied short- versus longer-course antibiotic therapy (the same
antibiotic at the same daily dosage) for adolescent and adult out-
patients with community-acquired pneumonia (CAP). We con-
cluded that the effects of antibiotic therapy duration for adoles-
cent and adult outpatients with CAP remain unclear.
Implications for research
The optimal duration of antibiotic therapy for people with CAP
is uncertain. There is a need for rigorous RCTs to determine the
efficacy and safety of short- versus long-course antibiotic therapy
(the same antibiotic at the same daily dosage) for adolescent and
adult outpatients with CAP. In particular, studies evaluating the
non-inferiority of short-course antibiotic therapy for efficacy, and
its superiority for safety are required.
A rigorous evaluation is relevant because short courses of antibi-
otics would reduce unnecessary antibiotic treatment, which may
limit the spread of drug-resistant bacteria, reduce treatment costs
and associated adverse events (including Clostridium difficile in-
fection), and improve treatment compliance (Bernal-Vargas 2016;
Chalmers 2016; Dinh 2016; Dunbar 2003; El Moussaoui 2006;
File 2004c; Garau 2008; Hopkins 1995; Kolditz 2005; Li 2007;
Mandell 2003; Pugh 2015; Socan 1998). Moreover, unnecessary
variability in clinical practice may be minimised because at present
there is no consensus on theminimumduration of antibiotic treat-
ment for adolescent or adult outpatients with CAP (Lim 2009;
Woodhead 2000).
Appendix 9 details the research that would be most desirable ac-
cording to the Evidence Population(s) Intervention Comparison
Outcomes Time stamp (EPICOT) format (Brown 2006). Future
trials should be rigorous in design and delivery, with adequate
reporting to enable appraisal and interpretation of results. Re-
searchers should report the studies in a standardised and infor-
mative format according to the following guidelines, among oth-
ers: CONSORT statement (Schulz 2010); extension of the CON-
SORT 2010 statement to non-inferiority and equivalence ran-
domised trials (Piaggio 2012); Template for Intervention Descrip-
tion and Replication (TIDieR) checklist (Hoffmann 2014); and
reporting guideline for health equity concerns in randomised con-
trolled trials (Welch 2017).
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There is an ongoing RCT that we will assess for inclusion in an
update of this review (NCT02903836).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aliberti 2017 RCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Coley 2000 CCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Darkes 2003 Ineligible design: review
Demartini 2004 RCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Donowitz 1997 RCT; ineligible intervention. Study did not assess the effects of antibiotic monotherapy duration
Dunbar 2003 RCT; ineligible comparison. Differences between study arms in antibiotic dose
Dunbar 2004 RCT; ineligible comparison. Differences between study arms in antibiotic dose
El Moussaoui 2006 RCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Fekete 2016 CCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
File 2004a RCT; ineligible comparison. Differences between study arms in antibiotic dose
File 2005 CCT; ineligible intervention. Study did not assess the effects of antibiotic monotherapy duration
File 2007 RCT; ineligible intervention. The antibiotic is not in current use for CAP
Fogarty 2001 CCT; ineligible intervention. Study did not assess the effects of antibiotic monotherapy duration
Hagberg 2003 CCT; ineligible intervention. Study did not assess the effects of antibiotic monotherapy duration
Hammerschlag 2003 RCT; ineligible intervention. Study did not assess the effects of antibiotic monotherapy duration
Hammerschlag 2007 CCT; ineligible design. Allocation sequence was not random.
Hammerschlag 2008 CCT; ineligible intervention. Study did not assess the effects of antibiotic monotherapy duration
Hemenway 2014 CCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Khashab 2006 CCT; ineligible intervention. Study did not assess the effects of antibiotic monotherapy duration
Lagler 2012 RCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Li 2007 Ineligible design: review
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(Continued)
Lorenz 2003 Ineligible design: review
Marti 2017 RCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
McCabe 1989 RCT; ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Niederman 2004a RCT; ineligible design. Pooled data from 2 RCTs
Niederman 2004b RCT; ineligible design. Post hoc analysis to investigate whether there were differences in overall healthcare
resource utilisation associated with 10 days of oral telithromycin 800 mg once daily versus 10 days of
clarithromycin twice daily in adults with CAP
Oldach 2015 RCT; ineligible comparison. Differences between study arms in antibiotic dose
Queen 2014 CCT; ineligible design. Observational study
Rasche 2015 CCT; ineligible design. Review
Rovira 1999 RCT; ineligible intervention. Did not consider antibiotic as monotherapy
Schonwald 1999 RCT; ineligible comparison. Differences between study arms in antibiotic dose
Shorr 2005 RCT; ineligible design. Subgroup analysis of an RCT
Tellier 2004 RCT; ineligible intervention. The antibiotic is not in current use for CAP
Van den Brande 1997 RCT;ineligible participants. Initial CAP treatment was provided for inpatients at hospital
Van Rensburg 2005 RCT; ineligible design. Pooled data from RCTs
Zhao 2015 RCT; ineligible comparison. Differences between study arms in antibiotic dose
Zhao 2016 RCT; ineligible comparison. Differences between study arms in antibiotic dose
CAP: community-acquired pneumonia
CCT: controlled clinical trial
RCT: randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
NCT02903836
Trial name or title Phase II study of oral nafithromycin in CABP
Methods Phase II
Randomised clinical trial
Blinding of participants, caregivers, investigators, and outcomes assessors
Participants Inclusion criteria:
Male and female
Aged 18 years or over
Clinical criteria for CABP based on the following:
1. clinical symptoms (new or worsening);
2. vital sign abnormalities;
3. laboratory abnormalities;
4. radiographic evidence of CABP;
5. PORT score.
Exclusion criteria:
People with any of the following confirmed or suspected types of pneumonia:
1. aspiration pneumonia;
2. hospital-acquired bacterial pneumonia;
3. healthcare-associated bacterial pneumonia;
4. ventilator-associated bacterial pneumonia;
5. pneumonia that may be caused by pathogen(s) resistant to either study drug;
6. receipt of 1 or more dose(s) of a potentially effective systemic antibacterial treatment for treatment of
the current CABP;
7. suspected or confirmed non-infectious causes of pulmonary infiltrates;
8. people requiring concomitant adjunctive or additional potentially effective systemic antibacterial
treatment for management of CABP.
Interventions Arm 1: nafithromycin 800 mg 3 days
Arm 2: nafithromycin 800 mg 5 days
Arm 3: moxifloxacin 400 mg
Outcomes Primary outcome:
1. clinical response in the ITT population (time frame: day 4)
Secondary outcomes:
1. clinical response in the micro-ITT population (time frame: day 4)
2. safety evaluation: number of participants with treatment-emergent adverse events, abnormal clinical
laboratory evaluation, abnormal vital signs, abnormal physical examination findings, and abnormal ECGs
during the treatment and follow-up phase (time frame: 31 days)
Starting date September 2016
Contact information Rakesh Chugh; rchugh@wockhardt.com
Notes This study compares oral nafithromycin versus oral moxifloxacin, a comparison not eligible for this review.
However, we hope that we will be able to extract the data of the comparison nafithromycin 800 mg 3 days
versus nafithromycin 800 mg 5 days
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CABP: community-acquired bacterial pneumonia
ECG: electrocardiogram
ITT: intention-to-treat
PORT: pneumonia patient outcomes research team
A P P E N D I C E S
Appendix 1. CENTRAL, MEDLINE, DARE search strategy
MEDLINE ALL (Ovid)
1 (communit* adj5 pneumon*).tw.
2 cap.tw.
3 Community-Acquired Infections/
4 (community-acquired or community acquired).tw.
5 3 or 4
6 exp pneumonia/
7 pneumon*.tw.
8 6 or 7
9 5 and 8
10 1 or 2 or 9
11 exp Anti-Bacterial Agents/
12 antibiotic*.tw.
13 exp Macrolides/
14 exp beta-Lactams/
15 exp Quinolones/
16 exp Tetracyclines/
17 (macrolide* or erythromycin* or azithromycin* or clarithromycin* or ketolides* or telithromycin* or beta-lactam* or amoxicillin*
or clavulanic* or co-amoxiclav* or cephalosporin* or cefuroxime* or cefotaxime* or ceftriaxone* or ceftibuten* or cefditoren*or
cefpodoxim* or quinolone* or fluoroquinalone* or moxifloxacin* or levofloxacin* or ampicillin* or trimethoprim* or oxytetracycline*
or doxycycline*).tw,nm.
18 or/11-17
19 10 and 18
The MEDLINE search was used to search CENTRAL, DARE and NHS EED.
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Appendix 2. Embase search strategy
Embase (Elsevier)
#1. ’community acquired pneumonia’/de
#2. (communit* NEAR/5 pneumon*):ab,ti
#3. cap:ab,ti
#4. ’communicable disease’/de
#5. ’community acquired’:ab,ti OR ’community-acquired’:ab,ti
#6. #4 OR #5
#7. ’pneumonia’/exp
#8. pneumon*:ab,ti
#9. #7 OR #8
#10. #6 AND #9
#11. #1 OR #2 OR #3 OR #10
#12. ’antibiotic agent’/exp
#13. antibiotic*:ab,ti
#14. ’macrolide’/exp OR ’beta lactam’/de OR ’quinolone derivative’/exp OR ’tetracycline derivative’/exp
#15. macrolide*:ab,ti OR erythromycin*:ab,ti OR azithromycin*:ab,ti OR clarithromycin*:ab,ti OR ketolide*:ab,ti OR telithromycin*:
ab,ti OR ’beta-lactam’:ab,ti OR ’beta-lactams’:ab,ti OR
amoxycillin*:ab,tiOR amoxicillin*:ab,tiOR clavulanic*:ab,tiOR ’co-amoxiclavulanate’:ab,tiOR cephalosporin*:ab,tiOR cefuroxime*:
ab,ti OR cefotaxime*:ab,ti OR ceftriaxone*:ab,ti OR
ceftibuten*:ab,ti OR cefditoren*:ab,ti OR cefpodoxin*:ab,ti OR quinolone*:ab,ti OR fluoroquinolone*:ab,ti OR moxifloxacin*:ab,ti
OR levofloxacin*:ab,ti OR ampicillin*:ab,ti OR trimethoprim*:ab,ti OR oxytetracycline*:ab,ti OR doxycycline*:ab,ti
#16. #12 OR #13 OR #14 OR #15
#17. #11 AND #16
#18. ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#19. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti
#20. #18 OR #19
#21. #17 AND #20
Appendix 3. CINAHL search strategy
CINAHL (EBSCO)
S1: (MH “Community-Acquired Pneumonia”)
S2: TI communit* N5 pneumon* or AB communit* N5 pneumon*
S3: TI CAP or AB CAP
S4: (MH “Community-Acquired Infections”)
S5: TI ( community acquired or community-acquired ) or AB ( community acquired or community-acquired )
S6: S4 or S5
S7 (MH “Pneumonia+”)
S8 TI pneumon* or AB pneumon*
S9 S7 or S8
S10 S6 and S9
S11: S1 or S2 or S3 or S10
S12: (MH “Antibiotics+”)
S13: TI antibiotic* or AB antibiotic*
S14: (MH “Antibiotics, Macrolide+”)
S15: (MH “Antiinfective Agents, Fluoroquinolone”)
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S16: (MH “Tetracyclines+”)
S17: TI ( macrolide* or azithromycin* or clarithromycin* or beta-lactam* or amoxicillin* or cephalosporin* or cefuroxime* or cefo-
taxime* or ceftriaxone* or quinolone* or fluoroquinalone* or moxifloxacin* or ampicillin* or trimethoprim* ) or AB ( macrolide* or
azithromycin* or clarithromycin* or beta-lactam* or amoxicillin* or cephalosporin* or cefuroxime* or cefotaxime* or ceftriaxone* or
quinolone* or fluoroquinalone* or moxifloxacin* or ampicillin* or trimethoprim* )
S18: S12 or S13 or S14 or S15 or S16 or S17
S19: S11 and S18
S20: (MH “Clinical Trials+”)
S21: PT clinical trial
S22: TI clinical* trial* or AB clinical* trial*
S23: TI ( singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*
) or AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*
)
S24: TI random* or AB random*
S25: (MH “Placebos”)
S26: TI placebo* or AB placebo*
S27: (MH “Quantitative Studies”)
S28: S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27
S29: S19 and S28
Appendix 4. LILACS search strategy
LILACS
> Search > (((MH:pneumonia OR MH:C08.381.677$ OR MH:C08.730.610$ OR Neumonía OR pneumon$ OR “Inflamación
del Pulmón” OR “Neumonía Lobar” OR Neumonitis OR “Inflamación Pulmonar” OR Pneumonía OR Pulmonía OR “Inflamação
do Pulmão” OR “Pneumonia Lobar” OR Pneumonite OR “Inflamação Pulmonar” OR Pulmonia) AND (MH:“Community-Ac-
quired Infections” OR “Infecciones Comunitarias Adquiridas” OR “Infecções Comunitárias Adquiridas” OR community OR Co-
munitarias OR Comunitárias)) OR cap OR “community-acquired pneumonia” OR “community acquired pneumonia”) AND (MH:
“Anti-Bacterial Agents” OR antibiotic$ OR Antibacterianos OR MH:D27.505.954.122.085$ OR Antibióticos OR MH:macrolides
OR Macrólidos OR Macrolídeos OR macrolid$ OR MH:D02.540.505$ OR MH:“beta-Lactams” OR “beta-Lactamas” OR MH:
D02.065.589.099$ OR MH:D02.886.108$ OR MH:D04.075.080.875.099.221$ OR betalactam$ OR “beta-lactam” OR “beta-
lactams” OR MH:quinolones OR Quinolonas OR MH: D03.438.810.835$ OR quinolon$ OR MH:Tetracyclines OR Tetracyclin$
OR Tetraciclinas ORMH: D02.455.426.559.847.562.900$ ORMH:D04.615.562.900$ OR erythromycin$ OR azithromycin$ OR
clarithromycin$ OR ketolid$ OR telithromycin$ OR amoxicillin$ OR clavulanic$ OR “co-amoxiclavulanic” OR “co amoxicavulanic”
OR coamoxyclavulanic$ OR cephalosporin$ OR cefuroxim$ OR cefotaxim$ OR ceftriaxon$ OR ceftibuten$ OR cefditoren$ OR
cefpodoxim$ OR fluoroquinalone$ OR moxifloxacin$ OR levofloxacin$ OR ampicillin$ OR trimethoprim$ OR oxytetracyclin$ OR
doxycyclin$) > trials filter
Appendix 5. Search strategy OpenGrey
OpenGrey
Pneumonia
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Appendix 6. ProQuest Dissertations & Theses search strategy
ProQuest Dissertations & Theses
ab(Antibiotic or antibiotics or macrolides or macrolide or beta-lactams or beta-lactam or betalactam or betalactams or quinolines or
quinoline or tetracyclines or tetracycline or erythromycin or azithromycin or clarithromycin or ketolides or ketolide or telithromycin or
amoxicillin or amoxicillin or clavulanic or co-amoxiclav or cephalosporin or cephalosporins or cefuroxime or cefotaxime or ceftriaxone
or ceftibuten or cefditoren or cefpodoxim or fluoroquinoline or fluoroquinolines or moxifloxacin or levofloxacin or ampicillin or
trimethoprim or oxytetracycline or doxycline) AND ab(pneumonia)
Appendix 7. Web of Science Conference Proceedings Citation Index Science search strategy
Web of Science CPCI-S
Topic=(Antibiotic or antibiotics or macrolides or macrolide or beta-lactams or beta-lactam or betalactam or betalactams or quinolones or
quinolone or tetracylines or tetracycline or erythromycin or azithromycin or clarithromycin or ketolides or ketolide or telithromycin or
amoxicillin or amoxycillin or clavulanic or co-amoxiclav or cephalosporin or cephalosporins or cefuroxime or cefotaxime or ceftriaxone
or ceftibuten or cefditoren or cefpodoxim or fluoroquinolone or fluoroquinolones or moxifloxacin or levofloxacin or ampicillin or
trimethoprim or oxytetracycline or doxycline) AND Topic=(pneumonia)
Refined by: Topic=(random* or placebo* or singl* blind* or doubl* blind* or clinical trial*)
Timespan=All Years. Databases=CPCI-S.
Appendix 8. Trials registers search strategy
Trials registers
1. ClinicalTrials.gov (www.clinicaltrials.gov)
“Interventional” [STUDY-TYPES] AND (Pneumonia OR Bronchopneumonia OR Pleuropneumonia) [CONDITION]
2. ISRCTN registry (www.isrctn.com/)
Condition: Pneumonia OR Bronchopneumonia OR Pleuropneumonia
3. WHO International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/Default.aspx)
Condition: Pneumonia OR Bronchopneumonia OR Pleuropneumonia
Recruitment status: Recruiting
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Appendix 9. Implications for research
5 days versus 10 days of amoxicillin for community-acquired pneumonia in adult outpatients: a non-inferiority RCT
Evidence 1. We found no eligible RCT that studied a short-course of antibiotic compared to a
long-course of antibiotic (with the same antibiotic at the same daily dosage) for CAP in
adolescent and adult outpatients. We have thus concluded that the effects of the
duration of antibiotic therapy for CAP in adolescent and adult outpatients is still
unclear.
2. Further studies are needed to determine the efficacy and safety of short-course
versus long-course antibiotic therapy (with the same antibiotic at the same daily
dosage) for CAP in adolescent and adult outpatients.
3. We propose here an RCT to assess the efficacy and safety of short-course (5 days)
versus long-course (10 days) of amoxicillin at the same daily dosage (1 g each 8 hours)
for CAP in adults managed in the outpatient setting.
4. We chose amoxicillin because it is an antibiotic commonly used in practice for the
treatment of CAP. However, other frequently used antibiotics may be evaluated as well,
such as other beta-lactams, macrolides, fluoroquinolones, cotrimoxazole, or
tetracyclines.
Comments
Population(s) Age: 18 to 65 years.
Gender: any.
Condition: CAP
1. Diagnosis of CAP (based on NICE
2014):
i) Symptoms and signs of an acute
lower respiratory tract infection (such as
altered breath sounds, localised rales, or
both)
ii) Confirmed by a chest x
ray showing new shadowing that is not
due to any other cause (such as
pulmonary oedema or infarction)
iii) The pneumonia must be
acquired outside the hospital setting or
within 48 hours of hospital admission
2. Severity of the CAP:
i) Not-severe CAP (CRB-65 score
= 0) (NICE 2014). CAP with severe
impairment will be excluded because it is
usually managed at the hospital:
impairment of consciousness, respiratory
rate > 30 breaths/min, heart rate > 125
beats/min, systolic blood pressure < 90
mmHg, diastolic blood pressure < 60
mmHg, temperature > 40 °C or oxygen
saturation < 92%.
Setting:
1. The diagnosis should be as similar as
possible to real practice, while still
ensuring that it is valid.
2. The study will not exclude
participants based on the presence
comorbidities such as diabetes or COPD,
in order to reflect routine clinical practice.
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1. Outpatients: CAP initially treated in
the community
2. Patients recruited in urban settings
3. Patients recruited in high- as well as
low- and middle-income countries
Intervention 1. Amoxicillin 1 g each 8 hours orally
during 5 days
2. Co-interventions: the antibiotic can
be used alone or in combination with
other interventions, such as antitussives,
antipyretics, bronchodilators, or
mucolytic.
1. The study design should allow the
effect of the duration of antibiotic course
to be evaluated.
2. Provide details of all the
interventions and co-interventions
undertaken, their compliance and their
acceptability.
3. In order to disentangle the effects of
the duration of the antibiotic course, the
same antibiotic at the same daily dosage
must be administered in all the study
arms. Moreover, the co-interventions
must be also similar in both study groups.
Comparison 1. Amoxicillin 1 g each 8 hours orally
during 10 days
2. Co-interventions: the antibiotic can
be used alone or in combination with
other interventions, such as antitussives,
antipyretics, bronchodilators, or
mucolytic.
Outcomes (from Barlow 2003) Include at least the following outcomes:
1. Symptoms and quality of life
measures
i) CAP-Sym (Lamping 2002)
2. Clinically based measures
i) Time to clinical stability (Halm
2002)*
ii) 30-day postadmission mortality
(Mortensen 2002)**
iii) Hospitalisation due to CAP
*Clinical instability, defined as fulfilling 1
or more of the following factors: tempera-
ture > 37.8 °C, pulse > 100/min, respira-
tory rate > 24/min, systolic blood pressure
<90mmHg, oxygen saturation<90%, lack
of availability of the oral route, and abnor-
mal mental status (Halm 2002).
**Not validated as an outcome measure,
but clearly important. 30 days’ follow-up is
the evidence-based time point
1. Measure, collect, and report
outcomes in an objective, reliable,
accurate, and actionable way.
2. Ensure blinding of participants,
caregivers, and outcome assessment
wherever possible to minimise
performance, attrition, and detection
biases.
3. Specify beforehand in the protocol
and assess relevant harms related to the
use of the antibiotic.
Time stamp Date of recommendation: July 2018
Study type RCT with the following study features:
1. Allocation procedure of
participants: concealed randomisation
2. Adequate sample size: calculate
RCT: type of study where the participants
(or groups of participants) are assigned
prospectively to an interventionor to a con-
trol group (or more than 1 control group)
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sample size using a non-inferiority or
equivalence criterion and specify the
margin of equivalence with the rationale
for its choice
3. Prospective parts of the study:
i) generation of hypothesis
ii) identification of participants
iii) assessment of baseline
iv) allocation to intervention
v) assessment of outcome
4. Study hypothesis:
i) effectivenness outcomes: non-
inferiority or equivalence
ii) safety outcomes: superiority
5. Blinding of participant and
personnel
6. Blinding of outcome assessment
7. Strategy of analysis
i) non-inferiority or equivalence
outcomes: per protocol
ii) superiority outcomes:
intention-to-treat
using a process of random allocation (e.g.
random number generation or coin flips)
. Randomisation ensures that participants
in each group should, at least theoretically,
differ only in their exposure to the inter-
vention - all other measurable characteris-
tics (such as gender, age, educational level,
smoking status, etc.) and those that can-
not be easily measured (such as attitude,
personal beliefs, etc.) should, by chance, be
distributed equally between the interven-
tion and control groups. This theoretically
ensures that the intervention and the con-
trol group differ only in the exposure to the
treatment (CCCG 2013).
Abbreviations: CAP: community-acquired pneumonia; CAP-Sym: Community-Acquired Pneumonia Symptom Questionnaire;
COPD: chronic obstructive pulmonary disease; CRB-65 score: confusion, respiratory rate, blood pressure, 65 years of age; RCT:
randomised controlled trial
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JLA RRB JRS;
JMG; JMMG; CRF;
JMC; JCC; MGG
JHM AAL VHS
Protocol devel-
opment
X X X
Guarantor X X
Contact person X
Piloted the selec-
tion stage
X X
Screened ti-
tles and abstracts
X X X X X
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and assessed full
texts
Resolution of
disagreements
X
Assessed confer-
ences
X X X X X
Designed
the data extrac-
tion form
X X
Piloted the data
extraction form
X X
Extracted data X X X
Resolution of
disagreements
X X
Cross-checking
extracted data
X X
’Risk of bias’ as-
sessment
X X X
Resolution of
disagreements
X X
Entered
data into Review
Manager 5
X
Data analysis X X
Checked
data entered into
Review Manager
5
X X X
Wrote the Back-
ground
X
Wrote the Meth-
ods sections of
the review
X X
33Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Wrote the Re-
sults,
Discussion, and
Authors’ conclu-
sions sections
X X X X
Prepared the
flow chart
X X
Prepared ’Sum-
mary of findings’
tables
X X
Made an intel-
lectual contribu-
tion and
provided clinical
perspective
X X X X X X
Edited the re-
view
X X X
Assessed
Methodological
Expectations of
Cochrane Inter-
vention Reviews
(MECIR) stan-
dards
X X X
Ap-
proved final ver-
sion of the review
prior to submis-
sion
X X X X X X
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Objectives
The original text in the protocol was “To evaluate the efficacy and safety of short-course versus long-course antibiotic therapy (with
the same antibiotic at the same daily dosage) for CAP in adolescent and adult outpatients. For efficacy outcomes, we will investigate
non-inferiority of short-course antibiotic treatment; for safety outcomes, we will investigate superiority”. The aim was the same, but
we expressed this differently in the review.
Types of studies
Following the standard text for the Methods section of the Cochrane Acute Respiratory Infections protocol, we added: “We included
studies reported as full text, those published as abstract only, and unpublished data”.
Types of interventions
The protocol stated that “...we anticipate that the class of antibiotic will be a relevant source of heterogeneity. Therefore, if we find
enough studies we will stratify the analysis by antibiotic type.” However, according to the suggestion of the Cochrane Acute Respiratory
Infections editorial team, we will meta-analyse studies regardless of whether they evaluate different types of antibiotics.
Types of outcome measures
We planned to assess the outcome “clinical response at the end-of-therapy evaluation visit” with a minimum follow-up of 14 days from
the beginning of treatment. However, we realised this minimum follow-up period was not compatible with certain antibiotic regimens
because the end-of-therapy evaluation visit occurred before this point. We therefore decided to consider the end-of-therapy evaluation
visit without a minimum follow-up.
The protocol planned to assess “patient compliance with treatment” (reported as dichotomous data where possible) as a secondary
review outcome. However, we reported the compliance as part of the description of the interventions, as suggested in the TIDieR
checklist and guide (Hoffmann 2014), and not as an outcome.
Search methods for identification of studies
The search strategy for MEDLINE differed slightly from the protocol, as follows.
1. We did not handsearch journals. All journals that appeared to have high yields of relevant studies had already been handsearched
on behalf of Cochrane.
2. We checked abstracts presented at the predefined conferences from 2004 onward (instead of 2000, as detailed in the protocol).
3. We could not search Asociación Latinoamericana del Tórax (ALAT) because it was not available.
4. We could not search 2004, 2006, and 2013 editions of NEUMOPED because they were not available.
5. We could not search 2011 and 2012 editions of PCRS because they were not available.
6. We searched CINAHL and OpenGrey (which were not planned in the protocol).
7. We did not consult IFPMA Clinical Trials Portal ( www.clinicaltrials.ifpma.org); visitors are now redirected to the WHO
International Clinical Trials Registry Platform.
8. We did not consult PhRMA Clinical Study Results Database (website no longer available).
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Assessment of risk of bias in included studies
• We planned to consider the tool described in the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0
(Higgins 2011a), rather than version 5.0.2 as proposed, because among other reasons the revised version assesses bias related to
blinding of participants and personnel in a domain separately from bias related to blinding of outcome assessment.
• We did not attempt to document the interrater reliability in the ’Risk of bias’ assessment using the kappa statistic or report
relevant discrepancies in the assessments (Higgins 2003).
• We planned to incorporate summary assessments of risk of bias for each outcome across studies into explicit measures of
evidence quality for each important outcome using the GRADE system (GRADEpro GDT 2014).
Sensitivity analysis
We could not perform sensitivity analysis.
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